
Riyadh, Kingdom of Saudi Arabia, December 16, 2025:
In a new strategic step to strengthen its presence in the Saudi market, and during its participation in the "Saudi Made” exhibition, EVA Pharma signed a Memorandum of Understanding with “Al Razi Pharma Industries”. The agreement aims to localize the manufacturing of advanced medical products for treating diabetes inside Saudi Arabia, supporting pharmaceutical security plans, and providing the latest treatments for patients.
This agreement represents an important pillar in the company's strategy for regional expansion. It aligns with "Saudi Vision 2030" to enhance local manufacturing in the healthcare sector. EVA Pharma not only aims to be present in the Saudi market but also to transfer advanced technology to localize the manufacturing of diabetes medicines with global quality, along with other important treatments and biological products. This ensures the sustainable availability of treatment for Saudi patients and contributes effectively to facing the challenges of chronic diseases in the region.
-Ends-
About EVA Pharma
EVA Pharma industry is a subsidiary of EVA Pharma Holding, one of the fastest-growing healthcare companies in the Middle East and Africa. EVA Pharma Industry is a local pharmaceutical manufacturer registered in Saudi Arabia, with a focus on sustainability and local investment in the Kingdom.
EVA Pharma is committed to improving access to high-quality medicines at an affordable price worldwide, focusing on 3 main pillars: Innovation, Development, and Sustainable Access. The company utilizes the latest technologies in two research centers, offering capabilities that are the first of their kind in the Middle East and Africa. This includes research and development in messenger RNA (mRNA), ranging from AI-based predictions to biological products.
A team of 5,000 professionals works at EVA Pharma. The company produces over one million healthcare products daily in four state-of-the-art manufacturing facilities. These facilities are internationally recognized for innovation and hold approvals from multiple regulatory authorities.
Led by a relentless drive to ensure sustainable access to urgent disease areas that have not yet been met, the company’s products focus on 12 therapeutic areas: Anti-infectives, Metabolic health, Orthopedics, Neuroscience, Oncology, Respiratory, Gynecology, Urology and Andrology, Pediatrics, Ophthalmology, Gastroenterology, and Family medicine. These cover both local and international demand.
For more information about the company, please visit https://www.evapharma.com/en-SA and https://www.evapharma.com/newsroom, or follow us on: X, LinkedIn, Instagram.
We empower the fight for health and well being as a human right.
Subscribe for our latest news and updates
For adverse events reporting, please contact us on
PV.Report@evapharma.com
This content is exclusively designed for healthcare professionals based in Saudi Arabia